GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaxis Pharmaceutical Corp (OTCPK:CURXQ) » Definitions » Enterprise Value

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Enterprise Value : $0.07 Mil (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Curaxis Pharmaceutical Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curaxis Pharmaceutical's Enterprise Value is $0.07 Mil. Curaxis Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil. Therefore, Curaxis Pharmaceutical's EV-to-EBIT ratio for today is -0.04.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Curaxis Pharmaceutical's Enterprise Value is $0.07 Mil. Curaxis Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil. Therefore, Curaxis Pharmaceutical's EV-to-EBITDA ratio for today is -0.04.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Curaxis Pharmaceutical's Enterprise Value is $0.07 Mil. Curaxis Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2011 was $0.00 Mil. Therefore, Curaxis Pharmaceutical's EV-to-Revenue ratio for today is .


Curaxis Pharmaceutical Enterprise Value Historical Data

The historical data trend for Curaxis Pharmaceutical's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaxis Pharmaceutical Enterprise Value Chart

Curaxis Pharmaceutical Annual Data
Trend Dec08 Dec09 Dec10 Dec11
Enterprise Value
- - 43.49 6.96

Curaxis Pharmaceutical Semi-Annual Data
Dec08 Dec09 Dec10 Dec11
Enterprise Value - - 43.49 6.96

Competitive Comparison of Curaxis Pharmaceutical's Enterprise Value

For the Drug Manufacturers - General subindustry, Curaxis Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curaxis Pharmaceutical's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaxis Pharmaceutical's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Curaxis Pharmaceutical's Enterprise Value falls into.



Curaxis Pharmaceutical Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Curaxis Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2011 is calculated as

Curaxis Pharmaceutical's Enterprise Value for the quarter that ended in Dec. 2011 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curaxis Pharmaceutical  (OTCPK:CURXQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Curaxis Pharmaceutical's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.070/-1.922
=-0.04

Curaxis Pharmaceutical's current Enterprise Value is $0.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curaxis Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Curaxis Pharmaceutical's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.070/-1.921
=-0.04

Curaxis Pharmaceutical's current Enterprise Value is $0.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curaxis Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Curaxis Pharmaceutical's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.070/0
=

Curaxis Pharmaceutical's current Enterprise Value is $0.07 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Curaxis Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2011 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curaxis Pharmaceutical Enterprise Value Related Terms

Thank you for viewing the detailed overview of Curaxis Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Curaxis Pharmaceutical (Curaxis Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Curaxis Pharmaceutical Corp was incorporated in Delaware on February 27, 2001. It is a specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease. The Company's therapeutic platform is based on the hypothesis that diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. Its discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable it to develop significant new treatments for Alzheimer's disease and may have applications for many cancers.
Executives
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Michael W George director C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Headlines

No Headlines